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Background: Recent publications have identified positive associations between numbers of lymph
nodes pathologically examined and five-year overall survival (5-yr OS) in colon cancer. However, focused
examinations of relationships between survival of rectal cancer and lymph node counts are less common. We
conducted a single institution, retrospective review of rectal cancer resections to determine whether lymph
node counts correlated with 5-yr OS and to explore the relationship between lymph node counts and various
clinical and pathologic factors.
Methods: A retrospective review of our institutional tumor registry identified 159 patients with AJCC Stage
1, 2, or 3 rectal cancers that underwent surgical resection at our institution over eleven years. Univariate
analysis was used to explore the relationship between lymph node counts and age, AJCC Stage, time period
of diagnosis, preoperative radiotherapy, and performance of TME. Survival analysis was performed by the
Kaplan-Meier method and the Cox proportional hazards model.
Results: In univariate analysis, there was an association between increased lymph node counts and age <70,
higher stage, and diagnosis during the later portion of the study period [all P-values <0.05]. Lymph node
counts were not associated with survival in Kaplan-Meier analysis or in multivariate Cox proportional
hazards analysis.
Conclusions: Increasing lymph node counts improve survival and the accuracy of colorectal cancer
staging. The body of literature recommends identical minimum lymph node counts in both colon and rectal
cancer. In our study, which exclusively examined rectal cancer, we could not demonstrate that increased
lymph node counts were associated with improved survival.
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Introduction
Colorectal cancer is the fourth leading cause of cancer and
the second leading cause of cancer death in the U.S. each
year. In the absence of distant metastatic disease, the status
of the regional lymph nodes is the most powerful prognostic
factor (1). Decisions regarding adjuvant chemotherapy and
chemoradiotherapy are based, in large part, on the presence
or absence of regional lymph node involvement. Given
the importance of regional lymph node status, efforts to
improve the accuracy of nodal staging are justified. The
accuracy of lymph node staging improves as the number of
lymph nodes pathologically examined increases (1). This
observation, which has been made in both colon and rectal
© Pioneer Bioscience Publishing Company. All rights reserved.

cancer, has led to consensus recommendations that at least
12 lymph nodes be identified and subjected to histological
examination in both colon and rectal cancer (2). This
recommendation has gained strength, and an additional
degree of importance, since the more recent publication
of studies that demonstrate that survival after resection for
colorectal cancer improves as the number of lymph nodes
examined increases. Indeed, those evaluating the quality
of care delivered in colon and rectal cancers are becoming
interested in using this recommendation as a quality
benchmark for both diseases (3,4).
This identical recommendation for minimum lymph
node examination in both colon and rectal cancer seems to
www.thejgo.org
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Table 1 Patient characteristics by number of lymph nodes
retrieved
Median nodes
Patient characteristic

N

retrieved [25th,

P-value

th

75 percent]
Gender
Female

78

7 [3,10]

Male

81

8 [3,10]

White

136

7 [3,10]

Black

20

9 [4,12]

Other

3

6 [5,9]

22-49

35

9 [5,14]

50-59

50

8 [5,11]

60-69

30

7 [3,9]

70+

44

6 [0,8]

I

87

5 [0,8]

II

28

8 [6,11]

III

44

10 [8,14]

1995-2000

95

6 [2,9]

2001-2005

64

8 [6,11]

No

133

7 [3,10]

Yes

26

7 [4,10]

No

79

8 [5,11]

Yes

30

9 [7,12]

N/A, missing, indet.

50

1 [0,7]

0.91

Race
0.43

Age group
0.0004*

AJCC
0.0001*

Year of diagnosis
0.0079*

Pre-op XRT/chemo
0.7206

MRE
0.001*

ignore two important points. It is generally understood that
lymph node counts are consistently lower in rectal cancer
specimens compared to colon cancer specimens. Second,
the body of evidence supporting an association between
higher lymph node counts and improved survival is heavily
weighted to analyses of colon cancer rather than rectal
cancer. Since the impact of lymph node counts in rectal
cancer seems less clear, we performed a retrospective review
to determine whether lymph node counts correlated with
5-yr OS and to explore the relationship between lymph
node counts and various clinical and pathologic factors.
Patients and methods
Through a search of our institutional tumor registry, we
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identified 190 patients with AJCC Stage 1, 2, or 3 rectal
adenocarcinoma that underwent surgical resection in our
hospital system over an eleven-year period (01/01/1995
through 12/31/2005). Institutional Review Board approval
was obtained to extract information from the database.
We defined rectal cancer patients as those with an invasive
tumor with its distal edge <15 cm from the anal verge.
We excluded 28 patients treated by transanal excision and
three that represented a recurrence from another primary
diagnosed before the beginning of our study period. We
then conducted a retrospective review of the medical
records of the remaining 159 patients to develop a database
containing standard clinico-pathologic variables.
The clinico-pathologic data recorded included the
following patient characteristics: age at diagnosis, gender,
AJCC stage, histological grade, LNCs, period of diagnosis
[1995-2000 and 2001-2005], administration of neoadjuvant
therapy, and performance of a detailed mesorectal excision.
LNCs were determined from the pathology report. For the
purpose of analyses, LNCs were dichotomized in 4 different
ways: ≥/<7, ≥/<10, ≥/<12, and ≥/<14, based on the median
number of lymph nodes examined in the current study
(i.e., 7) and values that appear in the literature (10, 12, and
14) (3,5,6).
Univariate analysis (Kruskal-Wallis test) was used to
explore the relationship between lymph node counts
and the following variables: age (<70 yrs/>70 yrs),
AJCC Stage, time of diagnosis (early — 19952000/late — 2001-2005), gender, administration of
neoadjuvant therapy and the performance of mesorectal
excision. Five-year OS was estimated by the KaplanMeier method and log rank testing was used to assess
potential differences between groups. Cox proportional
hazards modeling was used to examine the relationship
between lymph node counts and survival, adjusting
for patient age and stage at diagnosis. P-values ≤0.05
were considered statistically significant.
Results
Age, stage at diagnosis, year of diagnosis, and performance
of MRE were patient characteristics that were significantly
associated with LNCs. Patients less than 70 years old had
more lymph nodes retrieved compared to those ≥70 years
old (P<0.05). In univariate analysis, there was no statistically
significant difference in LNCs by gender or by the use of
neoadjuvant therapy (P>0.05). Patients treated during the
later years of the study were more likely to have more nodes
retrieved (P>0.05). Patients with MRE performed had
higher LNC, but not uniformly statistically significant for
each cut point of LNCs used (Tables 1,2).

www.thejgo.org
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Table 2 Univariate analysis of patient characteristics by number of lymph nodes retrieved
No. [%] w/≥

No. [%] w/≥

No. [%] w/≥

No. [%] w/≥

7 nodes

10 nodes

12 nodes

14 nodes

115

72 [62.6]

43 [37.4]

23 [20.0]

18 [15.7]

≥70 yrs

44

19 [43.2]

5 [11.4]

1[2.3]

1 [2.3]

P-value

-----

P=0.032*

P=0.001*

P=0.005*

P=0.026*

5 [5.8]

3 [ 3.5]

Patient characteristics

No. of Pts

Age at diagnosis
<70 yrs

AJCC stage
I

87

32 [36.8]

12 [13.8]

II

28

21 [75.0]

12 [42.9]

5 [17.9]

4 [14.3]

III

44

38 [86.4]

24 [54.6]

14 [31.8]

12 [27.3]

P<0.0001 *

P<0.0001 *

P=0.0003 *

P=0.0002 *

95

47 [49.5]

22 [23.2]

11 [11.6]

7 [7.4]

64

44 [68.8]

26 [40.6]

13 [20.3]

12 [18.8]

P=0.022*

P=0.023*

P=0.175

P=0.044*

P-value

-----

Year of diagnosis
1995-2000
2001-2005
P-value

-----

In our survival analysis, we observed that higher LNCs
were associated with lower survival rates. Although these
differences in survival were not statistically significant, they
were consistent for each cut point of LNCs used (Figure 1).
In multivariate survival analysis using the Cox proportional
hazards model, the apparent negative effect of increasing
LNCs on survival did not persist. In this analysis, only Stage
III disease and age over 70 yrs proved to be independent
predictors of the risk of death (Table 3). The performance
of MRE was not significant using the Cox proportional
hazards model and subsequently not used in survival
analysis.
Discussion
Colorectal cancer represents the second leading cause of
cancer related death in the U.S., resulting in 55,000 deaths
each year. In the absence of distant metastatic disease,
the status of the regional lymph nodes is the single most
powerful prognostic factor (1). The presence of lymph node
involvement, when matched for similar T-stage, results in
a decrease in 5-yr OS. Since the NIH consensus statement
regarding adjuvant therapy for colon and rectal cancer
was published in 1990, patients with node positive colon
or rectal cancer generally have been offered a 5-FU based
adjuvant chemotherapy regimen (7). The presence of nodal
involvement also increases the risk of regional recurrence
after rectal cancer resection, a risk that can be mitigated
by pelvic 5-FU based chemoradiotherapy. Accordingly,
Stage III rectal cancer patients are routinely offered such
chemoradiotherapy as part of a curative treatment regimen.

© Pioneer Bioscience Publishing Company. All rights reserved.

Given the importance of lymph node status in
determining prognosis and guiding treatment in colon
and rectal cancer, accurate staging of these diseases is an
important issue, both in the public health arena and for
individual patients and their physicians. Multiple studies
have demonstrated that the accuracy of staging in colorectal
cancer improves when more lymph nodes are histologically
examined (3,4). This fact, observed in both colon and
rectal cancer, has led to consensus recommendations to
identify and examine at least 12 lymph nodes from the
resected colon or rectal cancer specimen (2). The interest
in LNCs has escalated recently after the publication of a
similar observation that the probability of survival after
treatment for colon or rectal cancer improved in patients in
whom more lymph nodes were histologically examined (8).
Because of the relationship between LNCs and staging
accuracy and LNCs and survival, minimum LNCs are an
obvious target for those interested in evaluating the quality
of care in colorectal cancer (3).
It is interesting that, in spite of the fact that there
appear to be significant differences between colon cancer
and rectal cancer, the minimum LNC recommendations
do not discriminate between these two diseases (9). We
believe that this is unfortunate, since considering these two
disease as one disease process imprecisely characterizes
each and ignores important differences between them (10).
From an anatomical standpoint, the colon has a long
abundant mesentery that contains vascular structures and
rich lymphatics, while the rectal lymphatics are contained
in a much more compact and shortened mesentery. In
addition to these anatomic differences, the approaches to

www.thejgo.org
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A
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B
1.0

<7 lymph nodes
0.8

≥7 lymph nodes
0.6

Logrank P-value = 0.631

0.4

0.2

Cumulative proportion surviving

Cumulative proportion surviving

1.0

<10 lymph nodes
0.8

≥10 lymph nodes

0.6

Logrank P-value = 0.634

0.4

0.2

0.0

0.0

0

6

12

18

24

30

36

42

48

54

60

0

6

12

18

Time in months

30

36

42

48

54

60

Time in months

C

D
1.0

1.0

<12 lymph nodes

0.8

≥12 lymph nodes
0.6

Logrank P-value = 0.786

0.4

0.2

0.0

Cumulative proportion surviving

Cumulative proportion surviving

24

<14 lymph nodes

0.8

≥14 lymph nodes
0.6

Logrank P-value = 0.496

0.4

0.2

0.0

0

6

12

18

24

30

36

42

48

54

60

0

6

12

18

Time in months

24

30

36

42

48

54

60

Time in months

Figure 1 Kaplan-Meier estimates of 5-year overall survival by No. of lymph nodes retrieved

Table 3 Cox proportional hazards modeling controlling for age
and stage at diagnosis
Factor

Hazard ratio [95% CI]

P-value

Age at diagnosis
<70 yrs

Referent group

-----

≥70 yrs

5.47 [2.79,10.70]

0.0001*

1

Referent group

-----

2

2.06 [0.78,5.46]

0.146

3

4.16 [1.80, 9.62]

0.0009*

≥7 vs. <7

0.99 [0.48,2.04]

0.97

≥10 vs. <10

1.13 [0.54,2.38]

0.74

≥12 vs. <12

0.93 [0.39,2.26]

0.88

≥14 vs. <14

0.98 [0.38,2.49]

0.96

Stage at diagnosis

Lymph node comparisons

resecting the colon and rectal mesenteries differ. Standard
teaching dictates that a 5 cm bowel wall margin is required
on the proximal and distal ends of colon cancer resections.

© Pioneer Bioscience Publishing Company. All rights reserved.

However, this bowel margin is never a practical issue as
colon resections are based on the segmental, mesenteric
blood supply and lymphatic drainage of the part of the
colon to be resected. In rectal cancer resections, the
technical considerations are more complicated. While
most agree that the proximal bowel margin should be at
least 5 cm, the acceptable distal margin has been a source
of some disagreement/confusion (11). Historically, a 2 cm
distal margin on the bowel wall was considered adequate.
However, since Heald described the total mesorectal
excision in 1982, there has been a growing recognition that
the distal margin of importance in rectal resections is the
one on the mesorectum, and that this should be at least 4 cm
distal to the tumor (12). Our study suggests that attention to
the distal mesorectal margin might be suboptimal, as TME
was described in a minority of cases in our series. If this is
true of community practice in general, this combination
of mesenteric anatomic facts and differences in common
surgical techniques for mesenteric resection might explain
the gap in LNCs observed between colon cancer and rectal
cancer resections. It also makes a compelling argument for

www.thejgo.org
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additional studies that attempt to more clearly characterize
both the operative treatment of rectal cancer and the impact
this treatment has on outcome measures, such as LNCs, OS
and regional recurrence.
This consistent gap in LNCs between colon cancer and
rectal cancer makes it logical to pursue separate minimum
LNCs for each disease. Since we understand that more
appears to always be better when it comes to staging, we are
not necessarily arguing to decrease the minimum for LNCs
in rectal cancer. It might actually be more reasonable,
however, to increase the minimum LNCs for colon cancer.
This would then create some distinction between colon
and rectal cancer that reflects the current data. It might
also give those involved in quality oversight efforts a better
perspective on what constitutes an acceptable and fair
quality benchmark for LNCs in rectal cancer. It is also
worthwhile to remember the LNC is not the only factor in
determining outcomes after rectal cancer treatment (13).
Ultimately, lymph node count will be but one of many
factors considered in this disease. Because of the ease
of determination of LNCs, however, and the described
relationship between LNCs and survival, LNCs now
occupy a central place in the discussion.
In an effort to better understand the factors that affect
LNCs in rectal cancer, we explored the relationship between
LNCs and several clinico-pathologic factors. While gender
and race did not appear to affect LNCs, patient age did
seem to affect LNCs, as patients under 70 had higher LNCs
than those over 70. In addition, the period of diagnosis
was also important, as patients in our cohort diagnosed
after 2000 had higher LNCs. While this suggests some
change over time, we cannot readily identify the source of
that change. We suspect that increased awareness among
treating physicians and pathologists might have contributed
to the improvement in LNCs.
Another potential explanation for the increase in LNCs
could be a shift in the operative techniques being employed.
We did not observe any increase in the frequency of
TME performance but noticed an increase in LNCs in
those patients undergoing a TME. As suggested earlier,
we believe the impact of surgical techniques of rectal
resection on LNCs deserves more attention. Unfortunately,
larger, population-based data sets do not provide this
level of detail. Another potentially important factor in
rectal cancer and LNCs is the delivery of preoperative,
pelvic radiotherapy. Neoadjuvant radiotherapy is known
to decrease LNCs in the resected rectal cancer specimen.
Since neoadjuvant chemoradiotherapy has been accepted as
a standard treatment for node positive and Stage II rectal
cancers, efforts to use LNCs as a quality indicator will have
to consider the impact of this approach on this metric.

© Pioneer Bioscience Publishing Company. All rights reserved.
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One would assume that minimum LNCs would necessarily
be adjusted downward. Other clinical factors, such as the
clinical and or pathologic response to the preoperative
therapy might also have an impact on LNCs. Prior
studies have not considered patients who had undergone
neoadjuvant therapy (14,15). In the current study, there did
not appear to be any difference in LNCs between patients
who received preoperative chemoradiotherapy and those
who did not. One possible explanation for this negative
result might be that more patients received neoadjuvant
chemoradiatherapy in the later period, during which LNCs
increased. It is possible, therefore, that the negative impact
on LNCs expected because of preoperative radiotherapy
was masked by improved identification during the later
period of the study. Another possible explanation is that
our study simply lacked the power to detect a difference
in LNCs caused by preoperative radiotherapy. In either
case, future population-based studies should attempt
to characterize LNCs in patients who have undergone
preoperative radiotherapy and to determine whether LNCs
in this clinical setting carry the same importance as they
appear to carry in untreated patients.
While the improvement in staging accuracy with
increasing LNCs has been firmly established, the
relationship between lymph node counts and survival is
less settled. In the current study, no statistically significant
improvement in 5-yr OS was detected with increasing
LNCs. In fact, in Kaplan Meier analysis, higher lymph node
counts correlated with worse survival, albeit not statistically
significant either. This consistent observation, regardless
of how LNCs were dichotomized, is likely because
increasing LNCs were closely correlated with increasing
stage. It is difficult to imagine, based on the current data,
that an improvement in survival could be observed as
LNCs increase, since increasing LNCs are so closely tied
to increasing stage, and increasing stage is itself tied to
worse OS. We recognize that our inability to demonstrate
an improvement in survival with increasing LNCs does
not preclude the existence of such a relationship. In fact,
larger studies have provided more definitive information
on this relationship (5,15). It is worth pointing out that
large studies like these are crucial in detecting such
phenomena since institutionally based studies would be
much less likely to uncover them. Patient-level studies
remain important; however, because they provide more
granular clinical data that when analyzed teases out the why
and the how behind observations from population-based
studies. Combining individual institutional studies should
improve the productivity of this type of study. Perhaps the
most important role of these patient-level studies could be
to inform and improve the population-based registries by

www.thejgo.org

J Gastrointest Oncol 2013;4(2):158-163

Journal of Gastrointestinal Oncology, Vol 4, No 2 June 2013

suggesting which additional data should be collected by
these organizations.
The current study examines the relationship between
LNCs in resected rectal cancer and various clinicopathologic factors. Higher LNCs were associated with
younger age, higher stage, diagnosis in the later period
of our study, and performance of MRE. We could not
demonstrate a decrease in lymph node counts among
patients treated with neoadjuvant chemoradiotherapy.
Examination of the relationship between lymph node counts
and 5-yr OS failed to demonstrate any improvements in
survival with higher LNCs. In fact, the opposite effect
of higher LNCs was observed. Based on the apparent
differences between rectal cancer and colon cancer, we
believe separate recommendations for minimum lymph
node counts should be developed, based on populationbased data. We also believe that LNCs in patients treated
with preoperative chemoradiotherapy should be separately
analyzed to determine appropriate quality benchmarks.
Finally, recalling that LNC is not the only important factor,
institutionally based studies should continue to identify
other factors that influence outcomes after rectal cancer
treatment. These factors could then be considered for
inclusion in the data collection efforts of large populationbased registries.
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